{"doi":"10.58347/tml.2023.1678g","title":"Asciminib (Scemblix) for Chronic Myeloid Leukemia","abstract":"<jats:p>Asciminib (Scemblix – Novartis), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with ≥2 tyrosine kinase inhibitors and for adults with Ph+ CML in CP with a T315I mutation.</jats:p>","journal":"The Medical Letter on Drugs and Therapeutics","year":2023,"id":642852,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Asciminib (Scemblix) for Chronic Myeloid Leukemia","abstract":"<jats:p>Asciminib (Scemblix – Novartis), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with ≥2 tyrosine kinase inhibitors and for adults with Ph+ CML in CP with a T315I mutation.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37339100","pmcid":null,"openalex_id":"https://openalex.org/W4381469929","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.1209666,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://dx.doi.org/10.58347/tml.2023.1678g","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37339100","host_type":"repository"}],"fields_of_study":["Chronic Myeloid Leukemia Treatments","Chronic Lymphocytic Leukemia Research","HER2/EGFR in Cancer Research","Humans","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Pyrazoles","Niacinamide","Chronic Disease","Protein Kinase Inhibitors","Antineoplastic Agents","Drug Resistance, Neoplasm"],"mesh_terms":["Antineoplastic Agents","Chronic Disease","Humans","Niacinamide","Pyrazoles","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Drug Resistance, Neoplasm","Protein Kinase Inhibitors"],"keywords":["Myeloid leukemia","Medicine","Tyrosine-kinase inhibitor","Tyrosine kinase","Philadelphia chromosome","Dasatinib","Imatinib","Mutation","Cancer research","Internal medicine","Pharmacology","Biology","Cancer","Chromosomal translocation","Genetics","Receptor","Gene","Leukemia","Pregnancy","Safety","Lactation","Adverse effects","Dosage","Drug interactions","efficacy","Bosutinib","Ponatinib","Omacetaxine","Iclusig","Bosulif","Asciminib","Scemblix","Synribo"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-08T04:56:30.825611Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}